to our process. In addition, we appreciate the many comments on various drafts of this manuscript from Saul Walker, Veronika Wirtz, Wilbert Bannenberg, Marianne Schurmann, Anita Wagner, Corrina Moucheraud, Paul Shaw, Peter Berman, and Alex Preker. We thank the authors and co-authors who helped write the teaching cases. Their work illuminated the details of what happened in pharmaceutical reform around the world and contributed a great deal to our thinking. Those individuals are acknowledged for each case, but we would like to thank them here, as well: Anya Levy Guyer, Tory Ervin, Nathan J. Blanchet, Eric O. Moore, Laura Rock Kopczak, Prashant Yadav, Wilbert Bannenberg, Ramya Kumar, Pamela Norick, and the authors of the original report on microbicides in South Africa. We also thank the research assistants who contributed to the initial version of the book, including Nathan Blanchet, Anya Levy Guyer, Jean Leu, Hope O’Brien, Kate Powis, and Meghan Reidy, as well as Seemoon Choi and Juhwan Oh for their comments on case study C. We also express our appreciation to those who helped make possible the various versions of the course that played such a large role in the development of our ideas. They include Anne Mathiot and Tatiana Schofield at Imperial College London; Susan Gilbert and Anya Levy Guyer of the Harvard School of Public Health; and Wilbert Bannenberg, Elodie Brandamir, and Marieke Devillé of the MeTA Secretariat. Wilbert in particular has been our consultant, adviser, commentator, and, in Jordan, a co-teacher, in ways that have contributed much to our thinking and understanding. We thank Susan Gilbert for preparing a first draft of the glossary and Corrina Moucheraud for helping us organize the permissions for tables and figures. When it came time to put the manuscript into production, we received much help from the team at the World Bank’s Office of the Publisher, including our production editor, Mark Ingebretsen, our copy editor, Nancy Geltman, and others. Lastly, we express our deep appreciation to the more than one hundred individuals from more than a dozen countries who participated in the miniFlagship in London, the MeTA Pharmaceutical Flagship in Jordan, and the two pharmaceutical modules we offered at the Flagship Course in Washington, D.C. Their energy, interest, suggestions, examples, and advice have made the book more detailed and realistic than it would have been otherwise. Of course, neither they, nor any of our other partners and friends, are responsible for the views we take or for the errors that remain despite their efforts to prevent us from making them.
xx
Acknowledgments